We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New, Easy-To-Use CRISPR-Based HIV Test Kit to Deliver Results in Minutes

By LabMedica International staff writers
Posted on 11 Jul 2024
Print article
Image: The prototype HIV tester can potentially test and detect results in just minutes (Photo courtesy of University of Florida)
Image: The prototype HIV tester can potentially test and detect results in just minutes (Photo courtesy of University of Florida)

With 1.3 million new HIV cases and 630,000 HIV-related deaths reported in 2022 by the World Health Organization, improving and simplifying HIV detection in patients is crucial for reducing outbreaks and the resultant deaths. Although home testing kits for various health conditions have gained popularity, advancements in HIV testing have been slower to develop. Traditional HIV tests typically only become effective several weeks post-infection, raising the risk of unintentional virus transmission. Now, an innovative HIV-detection test kit utilizing advanced CRISPR technology is under development and could act as an early-warning system, potentially saving millions of lives.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, represents a breakthrough in genetic engineering, allowing selective modifications to the DNA of organisms in lab environments. This technology leverages genome editing systems that occur naturally in bacteria. A research team at the University of Florida (Gainesville, FL, USA) is nearing completion of their HIV detection method that employs CRISPR technology. Promising rapid results, this test could enable earlier treatment for patients, potentially reducing viral loads to undetectable levels.

The innovative CRISPR-based kit is designed to measure HIV RNA levels quickly using a compact microfluidic device. This palm-sized prototype facilitates rapid self-testing soon after potential exposure, delivering results within minutes. With additional development, this self-testing kit could be available for use in various settings, including homes, doctor's offices, community clinics, and outreach locations like homeless shelters, within the next five years. The team's initial research into this HIV testing method has yielded encouraging results.

“Our goal is to develop a test kit that is not only highly advanced but also user-friendly, like a reliable alarm that detects potential issues before they escalate,” said Piyush Jain, Ph.D., an assistant professor at UF’s Department of Chemical Engineering, who is leading the research team. “This research is crucial given the staggering global impact of HIV and the critical need for early detection.” 

Related Links:
University of Florida

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Nanoparticle Analyzer
Videodrop
New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
A schematic of the 3D MM imaging experimental setup used in the studies of blood films (Photo courtesy of Ushenko, A.G., et al.; doi.org/10.1038/s41598-024-63816-z)

Novel Light-Based Technique With 90% Accuracy Rate to Revolutionize Cancer Diagnosis

A quicker, cheaper, and less painful cancer detection technique developed using light has the potential to revolutionize cancer diagnosis, early detection, and monitoring. Researchers at Aston Institute... Read more

Industry

view channel
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)

Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications

QIAGEN N.V. (Venlo, the Netherlands) has entered into a collaboration with Eli Lilly and Company (Indianapolis, IN, USA) to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.